1. Home
  2. ENTO vs CETX Comparison

ENTO vs CETX Comparison

Compare ENTO & CETX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTO
  • CETX
  • Stock Information
  • Founded
  • ENTO 2014
  • CETX 1998
  • Country
  • ENTO United States
  • CETX United States
  • Employees
  • ENTO N/A
  • CETX N/A
  • Industry
  • ENTO Biotechnology: Pharmaceutical Preparations
  • CETX EDP Services
  • Sector
  • ENTO Health Care
  • CETX Technology
  • Exchange
  • ENTO Nasdaq
  • CETX Nasdaq
  • Market Cap
  • ENTO 1.9M
  • CETX 1.6M
  • IPO Year
  • ENTO 2016
  • CETX 1998
  • Fundamental
  • Price
  • ENTO $0.48
  • CETX $1.23
  • Analyst Decision
  • ENTO
  • CETX
  • Analyst Count
  • ENTO 0
  • CETX 0
  • Target Price
  • ENTO N/A
  • CETX N/A
  • AVG Volume (30 Days)
  • ENTO 1.6M
  • CETX 1.2M
  • Earning Date
  • ENTO 05-15-2025
  • CETX 08-13-2025
  • Dividend Yield
  • ENTO N/A
  • CETX N/A
  • EPS Growth
  • ENTO N/A
  • CETX N/A
  • EPS
  • ENTO N/A
  • CETX N/A
  • Revenue
  • ENTO N/A
  • CETX $73,816,291.00
  • Revenue This Year
  • ENTO N/A
  • CETX $19.77
  • Revenue Next Year
  • ENTO N/A
  • CETX $15.00
  • P/E Ratio
  • ENTO N/A
  • CETX N/A
  • Revenue Growth
  • ENTO N/A
  • CETX 12.93
  • 52 Week Low
  • ENTO $0.19
  • CETX $0.85
  • 52 Week High
  • ENTO $1.12
  • CETX $529.20
  • Technical
  • Relative Strength Index (RSI)
  • ENTO 52.62
  • CETX 53.05
  • Support Level
  • ENTO $0.39
  • CETX $1.20
  • Resistance Level
  • ENTO $0.41
  • CETX $1.40
  • Average True Range (ATR)
  • ENTO 0.06
  • CETX 0.14
  • MACD
  • ENTO 0.00
  • CETX 0.03
  • Stochastic Oscillator
  • ENTO 57.75
  • CETX 56.94

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

About CETX Cemtrex Inc.

Cemtrex Inc is a multi-industry technology company. It has expanded in a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security system. The company's operating segment includes, Security segment, Industrial Services segment and the corporate segment. The security segment provides end to end security to all industrial, corporate and governmental security via owned subsidiary Vicon. Whereas AIS part Industrial Service Segment is expertise services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. It generates maximum revenue from the Industrial Service Segment. It geographically operates in USA, UK and India, with maximum of revenue from USA.

Share on Social Networks: